Sign inJoin waitlistJoin the waitlist

Nora Bennani

Associate Professor of Medicine · Mayo Clinic College of Medicine and Science

Credentials: · · · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology/Oncology Oakland University William Beaumont School of Medicine
2007–2010
Cleveland Clinic
Internal Medicine
Fairview Hospital
2004–2007
Doctorate of Medicine University Hospital of Rabat
2001–2004
Doctor of Medicine
1997–2001

Research

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
Journal of Clinical Oncology · 2020 · 691 citations
C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review
Systematic review or meta-analysis · PLoS ONE · 2015 · 219 citations
Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease
Haematologica · 2020 · 169 citations

Stephen Ansell
48 papers
YL
Yi Lin
36 papers
Ronald Go
34 papers
Mithun Shah
32 papers
Gaurav Goyal
31 papers
KR
Karen Rech
31 papers
Patrick Johnston
30 papers
Jason Young
29 papers
Jonas Paludo
29 papers
Jithma Abeykoon
28 papers
Aishwarya Ravindran
27 papers · 18 as a resident
William Tobin
25 papers

Grants

Intravenous VSV Virotherapy in Lymphoma
National Cancer Institute · R01
PI · $1.8M · Mayo Clinic Rochester
2023–2029

Clinical trials

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Principal investigator · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2019–2024
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Site PI · Recruiting · Phase 2
Alliance for Clinical Trials in Oncology
2021–2027